Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

Reid, Alison H. M., Attard, Gerhardt, Brewer, Daniel ORCID:, Miranda, Susana, Riisnaes, Ruth, Clark, Jeremy, Hylands, Lucy, Merson, Sue, Vergis, Roy, Jameson, Charles, Høyer, Søren, Sørensen, Karina Dalsgaard, Borre, Michael, Jones, Chris, de Bono, Johann S. and Cooper, Colin S. ORCID: (2012) Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Modern Pathology, 25 (6). pp. 902-10. ISSN 1530-0285

Full text not available from this repository. (Request a copy)


There is increasing evidence that multiple chromosomal rearrangements occur in prostate cancer. PTEN loss is considered to be a key event in prostate carcinogenesis but the mechanisms of loss remain to be fully elucidated. We hypothesised that gross rearrangements may exist that cause disruption of the PTEN gene in the absence of genomic deletion. We therefore designed a novel fluorescence in situ hybridisation (FISH) assay with probes overlying regions 3' and 5' of PTEN and a third probe overlying the gene. We aimed to identify both genomic deletions and gross rearrangements of PTEN that would be overlooked by previously reported single-probe FISH assays. We proceeded to evaluate a tissue microarray with radical prostatectomy and trans-urethral resection of the prostate specimens from 187 patients. We identified PTEN genomic loss in 45/150 (30%) radical prostatectomy patients and 16/37 (43%) trans-urethral resection of the prostate patients. Importantly, our assay detected novel chromosomal alterations in the PTEN gene (characterised by splitting of FISH signals) in 13 tumours (6.9% of all prostate cancers; 21% of PTEN-lost cancers). All PTEN-rearranged tumours had genomic loss at the other allele and had no expression of PTEN by immunohistochemistry. PTEN-rearranged tumours were significantly more likely to have an underlying ERG rearrangement. Our assay differentiated loss of the probe overlying PTEN in isolation or in combination with either one of or both the probes overlying the 3' and 5' regions. This gave an indication of the size of genomic loss and we observed considerable inter-tumoural heterogeneity in the extent of genomic loss in PTEN-lost tumours. In summary, gross rearrangements of the PTEN locus occur in prostate cancer and can be detected by a 'break-apart' FISH assay. This observation could explain the absence of PTEN protein expression in a subgroup of tumours previously classified as having heterozygous genomic loss using single-probe traditional FISH assays.

Item Type: Article
Additional Information: An erratum is available which corrects one of the authors' names; the name is correct in the listing provided here. The content of the article is not affected.
Uncontrolled Keywords: aged,chi-square distribution,chromosome aberrations,gene rearrangement,genetic predisposition to disease,humans,immunohistochemistry,in situ hybridization, fluorescence,london,loss of heterozygosity,male,middle aged,norway,pten phosphohydrolase,phenotype,prostatectomy,prostatic neoplasms,time factors,tissue array analysis,trans-activators,treatment outcome,tumor markers, biological,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Science > School of Biological Sciences
Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User: Pure Connector
Date Deposited: 06 Jan 2014 14:16
Last Modified: 19 Oct 2023 01:13
DOI: 10.1038/modpathol.2011.207

Actions (login required)

View Item View Item